{"filing":{"accession_number":"0001193125-26-341229","cik":"0001798749","ticker":"JBIO","company_name":"Jade Biosciences, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d40629d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629d8k.htm"},"events":[{"id":26350,"run_id":23941,"accession_number":"0001193125-26-341229","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that \"Jade Biosciences, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated financial statements (balance sheet and statement of operations) showing Q2 2026 results including net loss of $55.8 million, R\u0026D expenses of $50.1 million, and cash position of $461.2 million, along with a corporate update on pipeline progress.","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27441,"accession_number":"0001193125-26-341229","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that \"Jade Biosciences, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated financial statements (balance sheet and statement of operations) showing Q2 2026 results including net loss of $55.8 million, R\u0026D expenses of $50.1 million, and cash position of $461.2 million, along with a corporate update on pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:14:37.750013+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27441,"accession_number":"0001193125-26-341229","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure explicitly states that \"Jade Biosciences, Inc. (the 'Company') issued a press release announcing the Company's financial results for the quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. The exhibit contains condensed consolidated financial statements (balance sheet and statement of operations) showing Q2 2026 results including net loss of $55.8 million, R\u0026D expenses of $50.1 million, and cash position of $461.2 million, along with a corporate update on pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:14:37.750013+00:00","company_name":"Jade Biosciences, Inc.","ticker":"JBIO","filing_date":"2026-08-10"}]}